InnoCare Pharma announced the completion of patient enrollment for the phase 2 clinical trial of ICP-488, a tyrosine kinase 2 (TYK2) JH2 allosteric inhibitor, for the treatment of psoriasis.

The multicenter, randomized, double-blind, placebo-controlled phase 2 study aims to evaluate the efficacy, safety, PK and PD characteristics of ICP-488 in Chinese adult patients with moderate to severe plaque psoriasis. A total of 129 patients were enrolled in this study. Patients were randomly assigned to one of three treatment groups in a 1:1:1 ratio, a 6 mg once-daily group, a 9 mg once-daily group, and a placebo group, for 12 consecutive weeks of treatment.

ICP-488 is an oral, potent and selective TYK2 allosteric inhibitor. By binding the JH2 domain, ICP-488 blocks the signal transduction of IL-23, IL-12, type 1 IFN and other inflammatory cytokine, thereby inhibiting the pathological process of autoimmune and inflammatory diseases. ICP-488 has demonstrated good efficacy and safety in the phase 1 study of treating psoriasis patients.

“Psoriasis requires long-term management, and there is still a significant unmet demand for new drugs, especially oral medications in its treatment. We are very pleased to see the completion of patient enrollment in the phase 2 clinical trial for the treatment of psoriasis with ICP-488," Dr. Jasmine Cui, Co-founder, Chairwoman and CEO of InnoCare said in a company news release. "We remain committed to diligently advancing the clinical development of this promising therapy, with the goal of providing improved treatment options to psoriasis patients as soon as possible.